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Abstract (250 words) 23 
The Anterior Gradient-2 (AGR2) is an Endoplasmic Reticulum (ER)-resident protein belonging to the 24 
Protein Disulfide Isomerase (PDI) family which mediates the formation of disulfide bonds, and assists 25 
the protein quality control in the ER. In addition to its role in proteostasis, extracellular AGR2 is 26 
responsible for various cellular effects in many types of cancer, including cell proliferation, survival, 27 
and metastasis. Various OMICs approaches have been used to identify AGR2 binding partners and to 28 
investigate the functions of AGR2 in the ER and outside the cell. Emerging data showed that AGR2 29 
exists not only as monomer, but it can also form homodimeric structure and thus interact with different 30 
partners, yielding different biological outcomes. In this review, we summarize the AGR2 31 
‘interactome’ and discuss the pathological and physiological role of such AGR2 interactions. 32 
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Introduction 
 Anterior gradient protein 2 (AGR2), also known as secreted cement gland protein XAG-2 33 
homolog, is a protein encoded in humans by the AGR2 gene, which belongs to the AGR subfamily 34 
(AGR2, AGR3 and TXNDC12 (AGR1)). AGR2 is located on chromosome 7p21, a region known to 35 
have frequent genetic alterations (42). AGR2 was originally discovered in Xenopus laevis (XAG-2 36 
gene) through dissection of different aged embryos (51). XAG-2 expression gathers at the anterior 37 
region of the dorsal ectoderm, which corresponds to the cement gland anlage (1). In another 38 
amphibian model, Salamander, AGR2 allows the regeneration of limbs from dedifferentiated cells and 39 
stem cells (28). AGR2 was first identified in humans in estrogen-receptor-positive breast cancer 40 
cells(52). Later studies demonstrated high expression of AGR2 in adenocarcinomas of the pancreas 41 
(11), esophagus (21, 44), lung (14, 43) and prostate (59). It is expressed strongly in tissues that secrete 42 
mucus or function as endocrine organs, including the lung, stomach, colon, prostate and small intestine 43 
(7). Furthermore, high expression of AGR2 protein in tissues that contain mucus-secreting cells and/or 44 
cells operative in endocrine organs supports a role for this protein in the epithelial barrier function. 45 
The positive regulation of the AGR2 promoter activity by Foxa1 and Foxa2, two transcription factors 46 
typical of epithelial goblet cells (7), also supports this hypothesis. 47 
 Studies have shown that the AGR2 protein can be localized to subcellular locations other than 48 
its typical ER residency. This AGR2 mislocalization results in interaction with a variety of cellular 49 
proteins involved in proteostasis control and signal transduction, and thus in cellular response. In 50 
Xenopus, AGR2 plays a role in cement gland differentiation (1), whereas in human cancer cell lines, 51 
high levels of AGR2 correlate with downregulation of the p53 response (44), cell migration, and cell 52 
transformation (57). AGR2’s physiological function might be that of a redox chaperone as it affects 53 
the folding of secreted proteins such as Alpha-1 antitrypsin and mucins (22), and the forming of mixed 54 
disulfides with protein substrates (39). Moreover, using an AGR2 knockout mouse lines, it has been 55 
demonstrated that AGR2 is essential for the secretion of the mucin MUC2 in intestinal Paneth and 56 
goblet cells (39, 60). Several laboratories have shown that this protein can act as either a monomer or a 57 
homodimer (34), depending on cellular demands or disease states. AGR2 displays a complex 58 
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biological network, as we discuss here. Furthermore, AGR2 expression levels and functionality have 59 
been altered in some pathologies, which leads us to argue that these changes may contribute to the 60 
onset or development of diseases such as cancer and inflammatory bowel disease, among others. 61 
 62 
A - AGR2 is a multidomain protein  63 
AGR2 has different roles that can be attributed to its multidomain structure. AGR2 is a protein 64 
composed of 175 amino acids with a molecular weight of 17 kDa (Figure 1). The encoded protein has 65 
an N-terminal ER-signal sequence, a catalytically active thioredoxin domain, and a C-terminal ER-66 
retention sequence (Figure 1). As an ER-localized molecular chaperone, it plays a role in the folding, 67 
trafficking, and assembly of cysteine-rich transmembrane receptors and the cysteine-rich intestinal 68 
glycoprotein mucin. From a structural point of view, it includes a particular signal sequence cleavable 69 
N-terminal to translocate into the ER (AA from 1 to 21) (Figure 1). AGR2 is believed to participate in 70 
protein folding, and it has a KTEL C-terminal motif (AA from 172 to 175 AA) (Figure 1) similar to 71 
KDEL and KVEL ER retention sequences (20). AGR2 protein belongs to the protein disulfide 72 
isomerase (PDI) family of ER proteins that catalyze protein folding and thiol-disulfide interchange 73 
reactions. Examination of AGR2 amino acid sequence reveals a single CXXS active domain motif 74 
(AA 81 to 84 ) (Figure 1) for oxidation and reduction reactions (17, 41), and the N-terminal region 75 
(AA 21 to 44) (Figure 1), which is responsible for the cell adhesion properties of AGR2 (18). In 76 
addition to being an ER-resident protein, AGR2 is also localized in cytoplasm (58), nucleus (30, 33), 77 
mitochondria (32), cell surface (12), extracellular matrix (14), and blood and urine (6, 13, 14), 78 
although the mechanism by which AGR2 accesses the cytoplasm, nucleus and extracellularly is 79 
unclear. 80 
 81 
B - Oligomeric Organizations and Interactome of AGR2  82 
B1. AGR-AGR2 interaction (monomer vs homodimer) 83 
The nature of AGR2 protein structure was not fully understood until the development of AGR2 crystal 84 
structure, which gives a clearer picture of AGR2 protein architecture. The Nuclear Magnetic 85 
Resonance (NMR) crystallography showed that AGR241-175 can exist in homodimer structure through a 86 
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motif EALYK at position E60-K64 (40). The salt bridge between the carboxylate group of E60 and 87 
the ammonium group of K64 forms the major interaction between the two AGR2 subunits in a reverse 88 
parallel fashion. Mutagenesis at this dimerization motif (E60A) abolishes the homodimeric structure. 89 
It is important to note that the dimerization interface of AGR2 is held far from the catalytic CXXS 90 
motif (opposing faces), where enhanced disulfide exchange in client proteins might occur. Although 91 
AGR2 has only one active cysteine residue (pseudo-thioredoxin domain) (Figure 1), the homodimeric 92 
structure of AGR2 might provide equivalent redox capacity. 93 
Alternatively, AGR2 can form a shaped homodimeric structure in which oxidation-dependent 94 
homodimerization occurs through C81-mediated disulfide bond formation (Figure 1), which would re-95 
orientate the homodimer into a different formation (49). Indeed, Clarke et al. showed that AGR2 can 96 
homodimerize in a similar fashion via the covalent bond (C81-C81) oxidation upon chemical peroxide 97 
exposure (8). The mutation of the single cysteine (C81) to alanine prevents hydrogen peroxide-98 
catalyzed homodimerization of AGR2. Additionally, mass spectrometry analysis reveals that low 99 
levels of a chemical oxidant promote an intermolecular disulfide bond through the formation of a 100 
labile sulfenic acid intermediate. However, higher levels of oxidant promote sulfinic or sulfonic acid 101 
formation, thus preventing covalent homodimerization of AGR2. The single cysteine (C81) of the 102 
AGR2 therefore acts as an oxidant-responsive moiety that regulates its tendency for oxidation and its 103 
monomeric-homodimeric state. 104 
AGR2 homodimerization is also associated with its N-terminal. The NMR study revealed that 105 
N-terminal amino acid region 21-40 (Figure 1) is unfolded (40). Deletion of the N-terminal disordered 106 
region (AA 21-45) (Figure 1) creates more stable AGR2 homodimer (18). Indeed, recombinant AGR2, 107 
having this deletion, demonstrated a spontaneous homodimer in solution, and this mutant showed 108 
enhanced binding to its client protein Reptin compared to wild type AGR2 (18). AGR2 was also 109 
shown to be capable of promoting cell adhesion by its N terminal domain (AA 21 to 44) (Figure 1). 110 
The monomeric AGR2 (E60A) or the native homodimeric AGR2 showed relatively similar cell 111 
adhesion properties, suggesting that homodimerization is not important for this property. As such, the 112 
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N-terminal could be an anchor, for example to the plastic surface (40), while the other part of AGR2 113 
interacts with cell receptors through thioredoxin motif or the facilitation of cell adhesion. 114 
Physiologically, this suggests that the monomer to homodimer equilibrium is important in 115 
AGR2 signaling. It also dictates the protein geometry and synergy between the homodimer interface 116 
and the catalytic thioredoxin motif, given that AGR2 has the sole C81 for thiol-disulfide interchange 117 
to assemble correctly folded disulfide bridges in client cargo proteins. High levels of homodimeric 118 
AGR2 might exist in the ER, which is important for cysteine-rich client protein folding. Recombinant 119 
AGR2 readily exists in homodimeric state in solution (8) consistent with the calculated monomer-120 
homodimer equilibrium dissociation constant, Kd of 8.83 μM (40). This provides an indication that 121 
homodimeric AGR2 might be a pre-dominant form in physiological condition. In addition, AGR2 can 122 
respond to oxidizing conditions which could affect the homodimer and monomer equilibrium. The ER 123 
environment, especially in the ER of cancer, is enriched in redox signaling mediators that in turn 124 
modulate the reactive oxygen species (ROS) (31). This creates a redox imbalance environment that 125 
can affect the monomeric and homodimeric equilibrium of AGR2 protein and this could give rise to 126 
AGR2 oncogenic functions.  127 
We have recently shown that the control of AGR2 homodimerization participates in the 128 
establishment of pro-inflammatory responses, which suggests that the AGR2 homodimer would 129 
behave as a sensor that contributes to the regulation of ER proteostasis (34). Using a protein–protein 130 
interaction screen to identify cellular regulators of AGR2 homodimerization, we discovered TMED2 131 
as a specific enhancer of AGR2 homodimerization. Further, we have characterized the interaction in 132 
vitro and in vivo and shown that upon ER stress, AGR2 and TMED2 dissociate. Finally, by a 133 
molecular modeling approach, we identified K66 and Y111 amino acid residues are involved in the 134 
TMED2-AGR2 interaction (Table 1, (34) ) 135 
This part of AGR2 functions are yet to be fully understood: (1) What are the roles and ratios 136 
of monomeric and homodimeric AGR2 in normal and disease conditions (e.g. cancer)?, (2) How does 137 
the oxidation and monomeric/homodimeric  state of AGR2 impact on client protein binding and client 138 
protein maturation, especially cysteine-rich proteins like MUC2?, (3) Could this affect the protein 139 
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folding capacity of AGR2 and shift its function to chaperone activity?, and (4) How does homodimeric 140 
AGR2 contribute to the progression of diseases such as cancer? 141 
B2. Insight into further AGR2 interactions 142 
Existing data shows that AGR2 can bind to a wide range of proteins such as nuclear, cytosolic 143 
and plasma membrane proteins. AGR2 interacting proteins validated using protein-protein interaction 144 
assays published in the literature largely belong to plasma membrane proteins (Table 1). This is not 145 
surprising since AGR2 is a PDI involved in the secretory pathway and therefore in the regulation of 146 
proteostasis, as we have reviewed recently (9). Such a function is supported by the observation that 147 
AGR2 can act as a PDI molecule critical for mucin biosynthesis (39). Another example is the AGR2 148 
binding partner, EGFR (Table 1), which can form mixed-disulfide bonds with AGR2. In this way, 149 
AGR2 controls EGFR cell surface delivery (10). This raises the question of how AGR2 can catalyze 150 
the folding, assembly, and trafficking of receptors such as EGFR to the cell surface. Moreover, one 151 
recent study showed that gene expression of EGFR ligand TGFA promotes the growth of mutant 152 
EGFRL858R lung tumor cells. AGR2 was found to be the key regulator as it was highly expressed in the 153 
TGFA-induced EGFR-mutant lung adenocarcinoma (55). AGR2 has also been shown to interact with 154 
cytoplasmic protein TAB2 (TGF-beta activated kinase 1) (58), ER and Golgi protein TMED2 (34), 155 
mitochondrial protein UNG1 (32), and nuclear transcription factor HIF-1α and Reptin (30, 33) (Table 156 
1). Some of AGR2 protein-protein interactions in the table 1 have been reviewed elsewhere (5, 7, 9). 157 
 Murray et al. used an in silico study to expand AGR2 interactome by exploiting the sequence-158 
specific peptide motif that binds to AGR2 which was previously identified using peptide-phage 159 
display (36). To our knowledge, AGR2 is the only PDI with such a specific peptide-binding activity. 160 
Attempts to define a consensus peptide binding site for AGR3 have been unsuccessful (data not 161 
shown). We hypothesize that if AGR2 can bind to this sequence-specific penta-peptide motif, it can 162 
also bind to proteins that have the same motif. To this end, a consensus AGR2 peptide motif was 163 
developed using synthetic peptide libraries. The consensus motif Tx[IL][YF[YF] was formed and this 164 
motif has been used to mine the human protein database to search for proteins harboring a similar 165 
motif. The data revealed that this motif is enriched in membrane-associated proteins, which suggest a 166 
role for AGR2 in this type of protein. Interestingly, none of the AGR2 client proteins identified in 167 
Downloaded from www.physiology.org/journal/ajpcell at INSERM (193.054.110.061) on December 10, 2019.
previous studies overlap with our database results, suggesting that this method is a first in terms of 168 
determining novel AGR2 client proteins and complements the classical PPI methods. One key receptor 169 
protein, EpCAM (Table 1), was validated as an AGR2 client protein using both in vitro and cell-based 170 
assays and maps of the binding interface using hydrogen deuterium mass spectrometry. The data 171 
suggests one plausible role of AGR2 in membrane trafficking – and thus in proteostasis – by ensuring 172 
the proper maturation of this class of protein type to their final destination through secretory pathway. 173 
However, it remains to be studied whether extracellular AGR2 (eAGR2) has extracellular activity for 174 
EpCAM since the ‘docking motif’ is located at the extracellular stalk of EpCAM. Other potential 175 
AGR2 proteins from this transmembrane database mining, including MKS3 (35) (Figure 3), are yet to 176 
be fully validated. Consistent with this EpCAM link to AGR2, quantitative shotgun proteomics was 177 
used to demonstrate that AGR2 and EpCAM were among the top upregulated cancer-associated 178 
proteins, and immunohistochemistry in esophageal adenocarcinoma tissues showed high expression of 179 
both proteins, thus presenting a novel biomarker pathway for this type of cancer (38). 180 
 The ability of AGR2 to interact with receptor proteins is not surprising as AGR2 was shown to 181 
be present in both ER (intracellular AGR2 (iAGR2)) and on the surface (extracellular AGR2 182 
(eAGR2)) of pancreatic cancer cells using immunofluorescence and flow cytometry (12). Localization 183 
of eAGR2 at the surface of the cell could suggest that AGR2 is attached to a client receptor protein. 184 
Moreover, eAGR2 can be secreted in the microenvironment and interact directly with the extracellular 185 
matrix (14). eAGR2 is also present in the extracellular mediums of pancreatic (46), colon (53) and 186 
lung (14) cancer cells, in the urine of prostate cancer patients (6), in the plasma of ovarian cancer 187 
patients (13), and in the serum of pituitary adenomas (54). In addition, atypical roles for eAGR2 have 188 
been reported in the tumor microenvironment (9). For example, the addition of exogenous AGR2 has 189 
been shown to promote angiogenesis through the regulation of hypoxia induced factor-1 (HIF-1) (23). 190 
We have previously demonstrated that eAGR2 performs an extracellular role independent of its ER 191 
function as an important microenvironmental pro-oncogenic regulator of epithelial  morphogenesis 192 
and tumorigenesis (14). Furthermore, eAGR2 can stimulate the insulin-like growth factor-1 receptor 193 
(IGF-1)-induced cell proliferation, migration and EMT in breast cancer cells through interaction with 194 
membrane ER-α (29). In colorectal cancer, eAGR2 can promote migration and metastasis through 195 
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Wnt11 signaling (53). This extracellular role of AGR2 has shifted the paradigm and current focus of 196 
how an ER-resident protein can exit the ER, be secreted to extracellular space and still retain its pro-197 
oncogenic effects. 198 
 199 
C- Physiological and pathological role of AGR interactome 200 
The biological network of AGR2 highlights the fact that AGR2 lies at the crossroads of 201 
multiple signaling pathways (Figure 2): Cell signaling, Proteostasis, Chemoresistance, Tumor cell 202 
dissemination and Protein trafficking. However, a number of important issues remain unsolved: (1) 203 
How are these interactions modulated?, (2) Which of them are relevant in physiological and 204 
pathological situations characterized by alterations in AGR2 expression levels, localization and/or 205 
function?, (3) Are these new interactions of AGR2 important to its role in key biological functions? In 206 
the following part, we will focus on these AGR2 reported physiological functions (Figure 2). 207 
 208 
C.1 AGR2 and proteostasis 209 
AGR2, as a PDI, is involved in the maturation of various proteins through forming disulfide 210 
bonds with mucins (Table 1), and directly regulating their processing and secretion. PDIs function to 211 
attain the highest quality and productivity of the ER and to therefore maintain ER protein homeostasis 212 
(also called proteostasis). In a healthy intestine, AGR2 acts as a critical modulator of intestinal 213 
homeostasis presenting within the ER of intestinal secretory epithelial cells (34) and regulating 214 
production of intestinal mucins via the formation of mixed disulfide bonds (60). Mice lacking AGR2 215 
expression are unable to produce intestinal mucins and are highly susceptible to colitis. 216 
Recently, AGR2 has also been shown to interact with UNG1 (Table 1) (32). UNG1 is 217 
important for initiating base-excision repair in mitochondria. Due to UNG1 being located in close 218 
proximity to the respiration chain, UNG1 is subject to oxidative damage. Liu et al. have demonstrated 219 
that overexpression of UNG1 enhances cell resistance to oxidative stress and protects mtDNA from 220 
oxidation. Thus, it has been suggested that the interaction of UNG1 and AGR2 stabilizes UNG1, 221 
through its PDI function, and enhances its enzymatic activity in DNA repair. However, more studies 222 
are needed to examine the nature and the physiological role of UNG1-AGR2 interaction. 223 
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We have previously demonstrated that AGR2 represents a mechanistic intermediate between 224 
endoplasmic reticulum quality control (ERQC) and tumor development (7, 22). Thus, “AGR2 225 
proteotasis” interactome in cancer could enhance proteostasis (Figure 2) thereby allowing tumor cells 226 
to cope with abnormal protein production and secretion and contributing to the tumor development. 227 
 228 
C.2 AGR2, a HIF-1α-binding stabilizer for chemoresistance properties 229 
In breast cancer, AGR2 has been shown to bind and stabilize HIF-1α (Table 1) (30), stabilize 230 
HIF-1α and delay its proteasomal degradation. It appears that AGR2 regulates the chemical hypoxia-231 
induced doxorubicin resistance in breast cancer cells, which explains the variable levels of 232 
chemoresistance in breast cancers. This further validates its role as a potential breast cancer 233 
therapeutic target. Hence, given the important role of AGR2/HIF-1α interactome in increasing 234 
chemoresistance in breast cancer, it would therefore be interesting to investigate the AGR2/HIF-1α 235 
pathway to develop strategies to block chemoresistance AGR2 properties (Figure 2) in breast cancer. 236 
C.3 AGR2 and tumor cell dissemination 237 
Reptin was identified by the yeast two-hybrid screen (Table 1) and validated as an interacting 238 
protein of AGR2 in human cells. Reptin is a highly conserved member of the AAA+ family that can 239 
be found in numerous multiprotein complexes linked to transcription, DNA damage response, and 240 
nonsense-mediated RNA decay (16, 24-27, 47). This protein is a member of the RuvBl1/2 superfamily 241 
containing ATP binding motifs and has the ability to form biologically relevant protein–protein 242 
interactions with proteins involved in cancer, including Myc, Tip60, APPL1, Pontin, and telomerase 243 
holoenzyme complexes (3, 4, 45, 47, 56). The ATP binding motifs of Reptin and the proposed 244 
substrate-binding loop of AGR2 are determinants that drive a specific complex between AGR2 and 245 
Reptin proteins (33). Reptin was also shown to be overproduced in primary breast cancer biopsy 246 
specimens, suggesting a role in cancer growth in vivo.  Because Reptin can also function as a 247 
prometastatic transcription protein, future research will inform whether AGR2 uses its substrate-248 
binding loop to chaperone Reptin into inactive and activated transcriptional states and/or whether the 249 
allosteric ATP-binding motifs of Reptin regulate AGR2 function as a prometastatic factor in cancer. 250 
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Orphan glycosyl-phosphatidyl-inositol-linked receptor, C4.4A, has been reported to interact 251 
with eAGR2 to induce cell proliferation, migration and chemoresistance in pancreatic ductal 252 
adenocarcinoma (2). The secreted proteins metastasis-associated GPI-anchored C4.4A protein and the 253 
extracellular domain of α-dystroglycan have been shown to directly interact with eAGR2, indicating 254 
potential mechanisms for eAGR2 in the promotion of tumor metastasis via the regulation of receptor 255 
adhesion and the interaction with the extracellular matrix (59, 60). 256 
Interestingly, C4.4A is a structural homologue of the urokinase-type plasminogen activator 257 
receptor (uPAR), which, along with CD59, is the most closely related human homologue of Prod1. In 258 
salamander limb regeneration, eAGR2 interacts with a cell surface receptor on adjacent cells identified 259 
as Prod1. Prod1 is a member of the three-finger protein (TFP) superfamily that is GPI-anchored at the 260 
cell surface. Whether CD59 is responsible for transducing the effect of eAGR2 is at present unknown. 261 
Prostate basal cells are immuno-stained by anti-CD59 and AGR2 (31). Therefore, it is possible to 262 
speculate that cells without CD59 might be resistant to the effect of eAGR2. Thus, eAGR2 interacts 263 
with the cell surface in order to modulate adhesion and promote tumor cell dissemination. 264 
A better understanding of the molecular mechanisms that promote the dissemination of tumor 265 
cells is essential for the development of novel detection and therapeutic strategies. For lung cancer, we 266 
have demonstrated that AGR2 induced the EMT and contributed to cancer dissemination (14). As 267 
AGR2 promotes the dissemination of tumor cells, we therefore suggest that “AGR2 tumor cell 268 
dissemination” interactome targeting may permit new strategies for therapeutic management against 269 
tumor cell dissemination capacity. 270 
C.4 AGR2 and regulation – the trafficking of proteins destined for the secretory pathway 271 
It has been established that AGR2 interacts physically with the Epithelial Growth Factor 272 
Receptor (EGFR) within the ER, and that this interaction is necessary before the receptor can progress 273 
to the Golgi apparatus and the plasma membrane (10). In pancreatic disease, it has been hypothesized 274 
that this AGR2-induced EGFR signaling forms a common and essential link between injury-induced 275 
tissue regeneration and the development of pancreatic cancer. AGR2 expression represents an early 276 
initiating event necessary for EGFR signaling, and thus serves as a potential target for the treatment of 277 
chronic and neoplastic pancreatic disease. In Pancreatic Ductal Adenocarcinoma (PDAC), AGR2 is 278 
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found activated downstream of mutant KrasG12D (11) and its important role in PDAC development was 279 
shown using both orthotopic and Kras-driven pancreatic cancer mouse model with the deletion of 280 
Smad4, a tumor suppressor gene frequently lost in the late stage (PanIN-3) of pancreatic 281 
carcinogenesis (11).  282 
Screening the human proteome for proteins that harbor a specific peptide motif 283 
(Tx[IL][YF][YF]) revealed an EpCAM-interaction (35). AGR2 binding to EpCAM seems to be in the 284 
ER, since the recombinant AGR2 and EpCAM binds in vitro. This recombinant protein is made in 285 
bacterial system, which lacks glycosylation – an event before post-translational modification that 286 
supports the hypothesis that AGR2-EpCAM binding is in the ER. EpCAM forms a model client 287 
protein for AGR2, which suggests that AGR2 is involved in regulating the trafficking of specific 288 
proteins destined for the secretory pathway, as has been demonstrated for EGFR. 289 
Thus, AGR2 not only plays an essential role in the secretory pathway via the “AGR2 290 
proteostasis” interactome (see C.1), but also via its protein-trafficking function. Thus, a protein 291 
trafficking network controlled by AGR2 could be a future target for anti-cancer therapy. 292 
 293 
C.5 AGR2-enhanced VEGF and FGF signaling  294 
We have demonstrated that AGR2 is a signaling molecule that is found outside cancer cells 295 
(eAGR2) and one that makes these cells more aggressive. Indeed, eAGR2 has several extracellular 296 
functions (9), including the promotion of angiogenesis- and fibroblast- coordinated tumor cell 297 
invasion. Indeed, eAGR2 has been reported to directly bind to VEGF and FGF2, are the major players 298 
in tumor angiogenesis, and enhance their activities (19). This enhancement is dependent on both the 299 
AGR2 self-homodimerization region and the signaling pathways of VEGF and FGF2. It has been 300 
shown, both in vivo and in vitro, that a monoclonal antibody targeting the AGR2 self-301 
homodimerization domain can partially abrogate eAGR2 activity. Thus, eAGR2 acts at multiple 302 
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 The increasing amount of data on AGR2 ‘interactome’ identifies this PDI as a signaling node 307 
involved in the regulation of cellular homeostasis. The intricacy of this network and the involvement 308 
of this protein in cancer-related processes has led us to argue that changes in AGR2 levels, localization 309 
and/or function have important roles to play in oncogenesis. This makes the AGR2 protein and its 310 
pathway a potential diagnostic marker and therapeutic target in cancer. Nevertheless, the biochemical 311 
mechanisms that explain how the AGR2 interactome is orchestrated based on the physiological 312 
context remains to be defined. The modulation of these potential AGR2 interactions, in addition to the 313 
overall physiological and pathological implications emerging from this AGR2 interaction map in 314 
disease context, are remain uncovered. We believe the AGR2 protein has a dual role, intracellular 315 
(iAGR2) and extracellular (eAGR2) (Figure 3). How AGR2 localization is regulated in normal and 316 
disease conditions, and how this impacts on client protein trafficking, are beginning to be defined. In 317 
summary, there is an intracellular chaperone role for AGR2 (iAGR2) in stimulating receptor 318 
maturation of pro-oncogenic proteins (EpCAM, EGFR) that can contribute to cancer growth. It 319 
appears that iAGR2 can stimulate receptor expression via transient binding to its sequence specific 320 
Tx[IL][YF][YF] motif in client proteins (docking-dependent) and through more stable interaction such 321 
as mixed disulfide bonding (docking independent) (Figure 3). Additional receptors identified with the 322 
peptide-binding motif include MUC16, FITM1, KCNC3, CXCR5 and OR2M4 (34). In addition, an 323 
extracellular role for AGR2 (eAGR2) may accelerate unidentified protein-protein interactions, which 324 
may be these same receptors as they function outside the cells that regulate cell-autonomy, as well as 325 
cell-cell interactions conducive to cancer cell proliferation. 326 
 In this context, increased understanding of the mechanisms and signals governing the 327 
expression, localization and function of AGR2 and other AGRs (AGR3 and TXNDC12) is crucial. 328 
Likewise, future investigations are needed to evaluate the effect of such changes on the complex 329 
coordinated network of AGR cellular functions as it is likely that altered AGR2 expression would 330 
differentially affect the function of its interacting partners and impair homeostasis/proteostasis in 331 
distinct ways.  332 
 In this context, the availability of specific AGR2 peptides will be advantageous in helping to 333 
clearly establish the physiological relevance of AGR2 ‘interactome’. New understanding of the AGR2 334 
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structure and the emerging identification of interaction domains will help to fine-tune and design 335 
peptides or molecules that are able to impair or disrupt such interactions selectively in order to target 336 
specific intracellular and extracellular functions of this PDI. 337 
  338 
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Figures legends 522 
Figure 1. Primary structure of the AGR2 protein.  523 
The colored boxes indicate the identified functional domains and amino acids involved in the 524 
regulation of AGR2 function. 525 
Figure 2. Physiological functions of AGR2.  526 
Schematic representation of AGR2 interactome that underlies its participation in key biological 527 
functions. 528 
Figure 3. Model of iAGR2 and eAGR2 functions in cancer. 529 
Schematic representation of iAGR2 and eAGR2 functions in cancer. AGR2 protein primarily resides 530 
in the ER, which helps to maintain proteostasis. Biochemical dissections have not yet been performed 531 
to explain how iAGR2 engages receptors as they enter the ER, the di-sulfide shuffling that is required 532 
to produce a fully folded receptor, and how vesicles can travel to the plasma membrane to deposit 533 
membrane receptors on the cell surface. Nevertheless, this model presents a framework for designing 534 
experimental protocols to answer such questions. There are a few AGR2 interactome assays that have 535 
been used to discover client receptor proteins and this was mainly discovered by protein-protein 536 
interaction assays. For example, classical co-immunoprecipitation assays have discovered EGFR (red) 537 
and Mucin (red) as an AGR2 interaction partner in which AGR2 can form mixed disulfide bond 538 
through its CXXS pseudo-thioredoxin motif. Additionally, a recent study demonstrated that AGR2 can 539 
bind to proteins containing an AGR2 sequence-specific peptide motif (Tx[IL][YF][YF]) and this was 540 
experimentally validated in the case of EpCAM (blue). Other proteins discovered from this database 541 
mining that harbor this peptide motif, including MKS3 (TMEM67), are yet to be fully validated.  542 
Thus, receptors like EpCAM (blue) and TMEM67 (MKS3; blue) appear to exploit this specific 543 
peptide-binding function of AGR2 to accelerate membrane expression. We consider these receptors 544 
iAGR2 ‘docking-dependent’ since mutation of the consensus-binding motif precludes proper plasma 545 
membrane expression of EpCAM (34) and TMEM67 (35). AGR2 can also be secreted and this 546 
eAGR2 was recently shown to play a critical role in regulating cell growth control promoting cancer 547 
development.  548 
   549 
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Table 1. List of AGR2 interacting proteins validated by protein-protein interaction assays. 561 











KDELR Co-IP KTEL motif (AA  




TMED2 ERMIT, Co-IP N-terminal/ 
dimer interface 
regions (K66 and 
Y111) 
(34) 
Plasma membrane DAG1 Y2H - (15) 
Plasma membrane LYPD3 Y2H - (15) 
Plasma membrane MUC1 Co-IP - (37) 
Plasma membrane MUC2 Co-IP CXXS motif (AA 
81 to 84 ) 
(39, 60) 
Plasma membrane Immature MUC5AC  Co-IP - (50) 
Plasma membrane MUC5B Co-localization - (50) 
Plasma membrane PROD1 (Axolotl homolog 
of human CD59) 
Y2H - (28) 
Plasma membrane EGFR Co-IP CXXS motif (AA 
81 to 84 ) 
(10) 




Structural loop  
VDPSL (AA 131 
to 135) 
(35) 











Cytoplasm REPTIN Y2H Domain (AA 104 
to 111) 
(33) 
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